Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma

被引：14

作者：

Belada, David ^{[1
]}

Georgiev, Pencho ^{[2
]}

Dakhil, Shaker ^{[3
]}

Inhorn, Lowell F. ^{[4
]}

Andorsky, David ^{[5
]}

Beck, J. Thaddeus ^{[6
]}

Quick, Donald ^{[7
]}

Pettengell, Ruth ^{[8
]}

Daly, Robert ^{[9
]}

Dean, James P. ^{[9
]}

Pavlyuk, Mariya ^{[10
]}

Failloux, Nelly ^{[10
]}

Huebel, Kai ^{[11
]}

机构：

[1] Charles Univ Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[2] UMHAT Sveti Georgi, Clin Haematol Clin, Plovdiv, Bulgaria

[3] Canc Ctr Kansas, Wichita, KS USA

[4] Blue Ridge Canc Care, Roanoke, VA USA

[5] Rocky Mt Canc Ctr, Boulder, CO USA

[6] Highlands Oncol Grp, Fayetteville, AR USA

[7] Joe Arrington Canc Res & Treatment Ctr, Lubbock, TX USA

[8] St Georges Healthcare NHS Trust, London, England

[9] CTI Biopharma Corp, Seattle, WA USA

[10] Inst Rech Int Servier, Suresnes, France

[11] Univ Hosp Cologne, Cologne, Germany

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 15期

关键词：

aggressive non-Hodgkin lymphoma; DLBCL; gemcitabine; pixantrone; relapse; rituximab; B-CELL LYMPHOMA; MULTICENTER PHASE-II; SINGLE-AGENT; MALIGNANT-LYMPHOMA; ADULT PATIENTS; REGIMENS; TRIAL; DRUG; CHOP;

D O I：

10.2217/fon-2016-0137

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma, who are ineligible for high-dose chemotherapy and stem cell transplantation, and who failed front-line regimens containing rituximab. The administration schedule is pixantrone 50 mg/m(2) intravenously (iv.) or gemcitabine 1000 mg/m(2) iv. on days 1, 8 and 15, combined with rituximab 375 mg/m(2) iv. on day 1, up to six cycles. Pixantrone has a conditional European marketing approval for monotherapy in adults with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Our trial explores the efficacy of combining pixantrone with rituximab and completes postauthorization measures. Trial registration number: NCT01321541.

引用

页码：1759 / 1768

页数：10

共 27 条

[1] Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions in solid tumor cell lines. [J].

Beeharry, Neil ;

Zhu, Xijun ;

Murali, Vignish ;

Smith, Mitchell R. ;

Yen, Timothy .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)

[2] Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma [J].

Boyle, Eileen Mary ;

Morschhauser, Franck .

EXPERT OPINION ON DRUG SAFETY, 2015, 14 (04) :601-607

[3]

Chan WC, 1997, BLOOD, V89, P3909

[4]

Chao Mark P, 2013, Cancer Manag Res, V5, P251, DOI 10.2147/CMAR.S34273

[5] Gemcitabine and its combinations in the treatment of malignant lymphoma [J].

Chau, I ;

Watkins, D ;

Cunningham, D .

CLINICAL LYMPHOMA, 2002, 3 (02) :97-104

[6] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[7]

Coiffier B, 1998, BLOOD, V92, P1927

[8] Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma [J].

Corazzelli, Gaetano ;

Capobianco, Gaetana ;

Arcamone, Manuela ;

Ballerini, Pier Ferruccio ;

Iannitto, Emilio ;

Russo, Filippo ;

Frigeri, Ferdinando ;

Becchimanzi, Cristina ;

Marcacci, Gianpaolo ;

De Chiara, Annarosaria ;

Pinto, Antonio .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (05) :907-916

[9] High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice [J].

Decaudin, Didier ;

Marszak, Fanny Baran ;

Couturier, Jerome ;

Mathiot, Claire ;

Martin, Antoine ;

Nemati, Fariba ;

Lantz, Olivier ;

di Santo, James ;

Arnaud, Philippe ;

Bordier, Vincent ;

Vincent-Salomon, Anne ;

Poupon, Marie-France .

ANTI-CANCER DRUGS, 2006, 17 (06) :685-695

[10] Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma [J].

Dumontet, C ;

Morschhauser, F ;

Solal-Celigny, P ;

Bouafia, F ;

Bourgeois, E ;

Thieblemont, C ;

Leleu, X ;

Hequet, O ;

Salles, G ;

Coiffier, B .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) :772-778

← 1 2 3 →